Form 4: Rapid Micro Biosystems CFO Granted Equity Awards

Rapid Micro Biosystems' Chief Financial Officer, Sean M. Wirtjes, received significant equity grants, including restricted stock units and stock options, effective February 11, 2026.

Summary

• Chief Financial Officer Sean M. Wirtjes was granted 97,000 Restricted Stock Units (RSUs) of Class A Common Stock.
• These RSUs vest in three annual installments: 33.4% on February 11, 2027, and 33.3% on February 11, 2028, and February 11, 2029, contingent on continuous service.
• Wirtjes also received 193,000 stock options with an exercise price of $4.2 per share.
• The stock options vest in 48 substantially equal monthly installments, beginning March 11, 2026, and expire on February 10, 2036.
• Following these transactions, Wirtjes beneficially owns 580,928 shares of Class A Common Stock and 193,000 stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, indicating management retention and alignment of interests, which is generally favorable for long-term stability.

Positives

• The grant of significant equity awards to the CFO aligns management's interests with long-term shareholder value.
• The multi-year vesting schedule for both RSUs and stock options incentivizes continuous service and performance over several years.

Negatives

• No immediate cash benefit for the CFO from these grants, as they are equity awards with vesting schedules.
• The stock options have an exercise price of $4.2, meaning the stock price must exceed this for them to be 'in the money' and provide value.

Risks

• The vesting of RSUs and exercisability of stock options are contingent upon the Reporting Person's continuous service with the company.

Future Outlook

The future outlook for the reporting person's beneficial ownership is tied to the vesting schedules of the granted RSUs and stock options, contingent on continuous service.

Industry Context

StockSavvy.ai notes that equity grants to key executives like the CFO are a standard practice across the biotechnology and diagnostics industry to attract, retain, and incentivize top talent, aligning their long-term interests with company performance and shareholder returns.

Comparison to Industry Standards

• Equity compensation packages, including RSUs and stock options with multi-year vesting schedules, are standard practice for executive compensation in the U.S. public markets, particularly in growth-oriented sectors like biotechnology.
• Companies such as Thermo Fisher Scientific (TMO) and Danaher Corporation (DHR) frequently utilize similar long-term incentive structures for their executive teams to foster retention and performance.

Stakeholder Impact

• Shareholders: Potential for increased long-term value creation due to incentivized management. Dilution from future share issuance upon RSU vesting and option exercise.
• Employees: May signal stability in executive leadership.

Next Steps

• Continued service by Sean M. Wirtjes to ensure vesting of equity awards.
• Monthly vesting of stock options beginning March 11, 2026.
• Annual vesting of Restricted Stock Units on February 11, 2027, 2028, and 2029.

Key Dates

Recommendation

The filing details routine executive compensation in the form of equity grants, which is a positive for aligning management incentives with shareholder interests. However, it does not provide new operational or financial performance data to warrant a change from a 'hold' position based solely on this information.

Keywords

Rapid Micro Biosystems, RPID, SEC Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, CFO, Executive Compensation